Metraipolis › archive › dc_07e97a035b7c

The role of memory in non-genetic inheritance and its impact on cancer treatment resistance — Europe PMC PMID:34460809

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34460809
DOI
10.1371/journal.pcbi.1009348
License (as archived)
CC0-1.0
Archived
2026-11-03T01:44:56.244Z
SHA-256 of the archived text
0bab733fd89fef60a46d9f2342f88238b06b3db41c11ad697fefa13828c35f9d
Stable URL of this page
https://metraipolis.com/documento/dc_07e97a035b7c

How to cite

The role of memory in non-genetic inheritance and its impact on cancer treatment resistance — Europe PMC PMID:34460809 — Europe PMC (en), https://europepmc.org/article/MED/34460809 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_07e97a035b7c (Metraipolis archive dc_07e97a035b7c, sha256 0bab733fd89fef60a46d9f2342f88238b06b3db41c11ad697fefa13828c35f9d)
BibTeX
@misc{dc07e97a035b7c,
  title = {The role of memory in non-genetic inheritance and its impact on cancer treatment resistance — Europe PMC PMID:34460809},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34460809},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_07e97a035b7c; sha256 0bab733fd89fef60a46d9f2342f88238b06b3db41c11ad697fefa13828c35f9d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34460809. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Intra-tumour heterogeneity is a leading cause of treatment failure and disease progression in cancer. While genetic mutations have long been accepted as a primary mechanism of generating this heterogeneity, the role of phenotypic plasticity is becoming increasingly apparent as a driver of intra-tumour heterogeneity. Consequently, understanding the role of this plasticity in treatment resistance and failure is a key component of improving cancer therapy. We develop a mathematical model of stochastic phenotype switching that tracks the evolution of drug-sensitive and drug-tolerant subpopulations to clarify the role of phenotype switching on population growth rates and tumour persistence. By including cytotoxic therapy in the model, we show that, depending on the strategy of the drug-tolerant subpopulation, stochastic phenotype switching can lead to either transient or permanent drug resistance. We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population extinction and avoids competitive release of the drug-tolerant sub-population. This model-informed therapeutic schedule results in increased treatment efficacy when compared against periodic therapy, and, most importantly, sustained tumour decay without the development of resistance.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2021 (prima pubblicazione 2021-08-30).
Identificativi: PMID 34460809 · PMCID PMC8432806 · DOI 10.1371/journal.pcbi.1009348.
Pagina: https://europepmc.org/article/MED/34460809 — https://doi.org/10.1371/journal.pcbi.1009348. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-03T01:37:52.650Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.